Elevated plasma lipoprotein (a)(LPA) levels are recognized as an independent risk factor for
cardiovascular diseases. Our knowledge on LPA metabolism is incomplete, which makes it
difficult to develop LPA-lowering medications. Nicotinic acid (NA) is the main drug
recommended for the treatment of patients with increased plasma LPA concentrations. The
mechanism of NA in lowering LPA is virtually unknown. To study this mechanism, we treated
transgenic (tg) APOA mice with NA and measured plasma APOA and hepatic mRNA levels …